

Global Metachromatic Leukodystrophy Treatment Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/G3C2AB3E4B9FEN.html>

Date: February 2023

Pages: 110

Price: US\$ 3,660.00 (Single User License)

ID: G3C2AB3E4B9FEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Metachromatic leukodystrophy disease (MLD) is a deadly genetic condition caused by mutations in the ARSA gene that results in brain impairment and developmental retardation. In its most severe and prevalent forms, young children rapidly lose their capacity to walk, communicate, and interact with their surroundings, and the majority die before reaching puberty. Metachromatic leukodystrophy is characterized by sulfatide deposition in cells. This accumulating has a particular impact on nervous system cells that create myelin, a material that insulates and protects neurons. White matter is a tissue made composed of nerve cells coated with myelin. This damages the protective myelin sheathing the neurons, leading to gradual deterioration of the brain and nervous system functioning. This disease has three forms that are Late Infantile Form, Juvenile Form, and Adult Form. Pipeline products, which can only treat symptoms of the disease, are among the medical treatment. These products have the potential to prevent nerve damage, reduce the development of the illness, avoid complications, and provide pain relief.

LPI (LP Information)' newest research report, the "Metachromatic Leukodystrophy Treatment Industry Forecast" looks at past sales and reviews total world Metachromatic Leukodystrophy Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Metachromatic Leukodystrophy Treatment sales for 2023 through 2029. With Metachromatic Leukodystrophy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Metachromatic Leukodystrophy Treatment industry.

This Insight Report provides a comprehensive analysis of the global Metachromatic

Leukodystrophy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Metachromatic Leukodystrophy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Metachromatic Leukodystrophy Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Metachromatic Leukodystrophy Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Metachromatic Leukodystrophy Treatment.

The global Metachromatic Leukodystrophy Treatment market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Metachromatic Leukodystrophy Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Metachromatic Leukodystrophy Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Metachromatic Leukodystrophy Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Metachromatic Leukodystrophy Treatment players cover ArmaGen, Inc., GlaxoSmithKline Plc, Recursion Pharmaceuticals, Inc., RegenxBio, Inc., Takeda Pharmaceutical Company Limited, Orchard Therapeutics Plc, Magenta Therapeutics, Shire Plc and Oxyrane, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth

opportunities of Metachromatic Leukodystrophy Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Tablet

Capsule

Others

Segmentation by application

Hospital

Clinic

Laboratory

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its

market penetration.

ArmaGen, Inc.

GlaxoSmithKline Plc

Recursion Pharmaceuticals, Inc.

RegenxBio, Inc.

Takeda Pharmaceutical Company Limited

Orchard Therapeutics Plc

Magenta Therapeutics

Shire Plc

Oxyrane

NanoMedSyn

Juventas Therapeutics

GenSight Biologics

Inozyme Pharma

ONL Therapeutics

AngioChem

Cabaletta Bio

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Metachromatic Leukodystrophy Treatment Market Size 2018-2029
 - 2.1.2 Metachromatic Leukodystrophy Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Metachromatic Leukodystrophy Treatment Segment by Type
 - 2.2.1 Tablet
 - 2.2.2 Capsule
 - 2.2.3 Others
- 2.3 Metachromatic Leukodystrophy Treatment Market Size by Type
 - 2.3.1 Metachromatic Leukodystrophy Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
 - 2.3.2 Global Metachromatic Leukodystrophy Treatment Market Size Market Share by Type (2018-2023)
- 2.4 Metachromatic Leukodystrophy Treatment Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 Laboratory
 - 2.4.4 Others
- 2.5 Metachromatic Leukodystrophy Treatment Market Size by Application
 - 2.5.1 Metachromatic Leukodystrophy Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
 - 2.5.2 Global Metachromatic Leukodystrophy Treatment Market Size Market Share by Application (2018-2023)

3 METACHROMATIC LEUKODYSTROPHY TREATMENT MARKET SIZE BY PLAYER

3.1 Metachromatic Leukodystrophy Treatment Market Size Market Share by Players

3.1.1 Global Metachromatic Leukodystrophy Treatment Revenue by Players (2018-2023)

3.1.2 Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Players (2018-2023)

3.2 Global Metachromatic Leukodystrophy Treatment Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 METACHROMATIC LEUKODYSTROPHY TREATMENT BY REGIONS

4.1 Metachromatic Leukodystrophy Treatment Market Size by Regions (2018-2023)

4.2 Americas Metachromatic Leukodystrophy Treatment Market Size Growth (2018-2023)

4.3 APAC Metachromatic Leukodystrophy Treatment Market Size Growth (2018-2023)

4.4 Europe Metachromatic Leukodystrophy Treatment Market Size Growth (2018-2023)

4.5 Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas Metachromatic Leukodystrophy Treatment Market Size by Country (2018-2023)

5.2 Americas Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2023)

5.3 Americas Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Metachromatic Leukodystrophy Treatment Market Size by Region (2018-2023)

6.2 APAC Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2023)

6.3 APAC Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2023)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Metachromatic Leukodystrophy Treatment by Country (2018-2023)

7.2 Europe Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2023)

7.3 Europe Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Metachromatic Leukodystrophy Treatment by Region (2018-2023)

8.2 Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2023)

8.3 Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2023)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL METACHROMATIC LEUKODYSTROPHY TREATMENT MARKET FORECAST

10.1 Global Metachromatic Leukodystrophy Treatment Forecast by Regions (2024-2029)

10.1.1 Global Metachromatic Leukodystrophy Treatment Forecast by Regions (2024-2029)

10.1.2 Americas Metachromatic Leukodystrophy Treatment Forecast

10.1.3 APAC Metachromatic Leukodystrophy Treatment Forecast

10.1.4 Europe Metachromatic Leukodystrophy Treatment Forecast

10.1.5 Middle East & Africa Metachromatic Leukodystrophy Treatment Forecast

10.2 Americas Metachromatic Leukodystrophy Treatment Forecast by Country (2024-2029)

10.2.1 United States Metachromatic Leukodystrophy Treatment Market Forecast

10.2.2 Canada Metachromatic Leukodystrophy Treatment Market Forecast

10.2.3 Mexico Metachromatic Leukodystrophy Treatment Market Forecast

10.2.4 Brazil Metachromatic Leukodystrophy Treatment Market Forecast

10.3 APAC Metachromatic Leukodystrophy Treatment Forecast by Region (2024-2029)

10.3.1 China Metachromatic Leukodystrophy Treatment Market Forecast

10.3.2 Japan Metachromatic Leukodystrophy Treatment Market Forecast

10.3.3 Korea Metachromatic Leukodystrophy Treatment Market Forecast

10.3.4 Southeast Asia Metachromatic Leukodystrophy Treatment Market Forecast

10.3.5 India Metachromatic Leukodystrophy Treatment Market Forecast

10.3.6 Australia Metachromatic Leukodystrophy Treatment Market Forecast

10.4 Europe Metachromatic Leukodystrophy Treatment Forecast by Country (2024-2029)

10.4.1 Germany Metachromatic Leukodystrophy Treatment Market Forecast

10.4.2 France Metachromatic Leukodystrophy Treatment Market Forecast

10.4.3 UK Metachromatic Leukodystrophy Treatment Market Forecast

10.4.4 Italy Metachromatic Leukodystrophy Treatment Market Forecast

10.4.5 Russia Metachromatic Leukodystrophy Treatment Market Forecast

10.5 Middle East & Africa Metachromatic Leukodystrophy Treatment Forecast by Region (2024-2029)

10.5.1 Egypt Metachromatic Leukodystrophy Treatment Market Forecast

10.5.2 South Africa Metachromatic Leukodystrophy Treatment Market Forecast

10.5.3 Israel Metachromatic Leukodystrophy Treatment Market Forecast

10.5.4 Turkey Metachromatic Leukodystrophy Treatment Market Forecast

10.5.5 GCC Countries Metachromatic Leukodystrophy Treatment Market Forecast

10.6 Global Metachromatic Leukodystrophy Treatment Forecast by Type (2024-2029)

10.7 Global Metachromatic Leukodystrophy Treatment Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 ArmaGen, Inc.

11.1.1 ArmaGen, Inc. Company Information

11.1.2 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Product Offered

11.1.3 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.1.4 ArmaGen, Inc. Main Business Overview

11.1.5 ArmaGen, Inc. Latest Developments

11.2 GlaxoSmithKline Plc

11.2.1 GlaxoSmithKline Plc Company Information

11.2.2 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Product Offered

11.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.2.4 GlaxoSmithKline Plc Main Business Overview

11.2.5 GlaxoSmithKline Plc Latest Developments

11.3 Recursion Pharmaceuticals, Inc.

11.3.1 Recursion Pharmaceuticals, Inc. Company Information

11.3.2 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Product Offered

11.3.3 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.3.4 Recursion Pharmaceuticals, Inc. Main Business Overview

11.3.5 Recursion Pharmaceuticals, Inc. Latest Developments

11.4 RegenxBio, Inc.

11.4.1 RegenxBio, Inc. Company Information

11.4.2 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Product Offered

- 11.4.3 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
- 11.4.4 RegenxBio, Inc. Main Business Overview
- 11.4.5 RegenxBio, Inc. Latest Developments
- 11.5 Takeda Pharmaceutical Company Limited
 - 11.5.1 Takeda Pharmaceutical Company Limited Company Information
 - 11.5.2 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Product Offered
 - 11.5.3 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.5.4 Takeda Pharmaceutical Company Limited Main Business Overview
 - 11.5.5 Takeda Pharmaceutical Company Limited Latest Developments
- 11.6 Orchard Therapeutics Plc
 - 11.6.1 Orchard Therapeutics Plc Company Information
 - 11.6.2 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Product Offered
 - 11.6.3 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.6.4 Orchard Therapeutics Plc Main Business Overview
 - 11.6.5 Orchard Therapeutics Plc Latest Developments
- 11.7 Magenta Therapeutics
 - 11.7.1 Magenta Therapeutics Company Information
 - 11.7.2 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Product Offered
 - 11.7.3 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.7.4 Magenta Therapeutics Main Business Overview
 - 11.7.5 Magenta Therapeutics Latest Developments
- 11.8 Shire Plc
 - 11.8.1 Shire Plc Company Information
 - 11.8.2 Shire Plc Metachromatic Leukodystrophy Treatment Product Offered
 - 11.8.3 Shire Plc Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.8.4 Shire Plc Main Business Overview
 - 11.8.5 Shire Plc Latest Developments
- 11.9 Oxyrane
 - 11.9.1 Oxyrane Company Information
 - 11.9.2 Oxyrane Metachromatic Leukodystrophy Treatment Product Offered
 - 11.9.3 Oxyrane Metachromatic Leukodystrophy Treatment Revenue, Gross Margin

and Market Share (2018-2023)

11.9.4 Oxyrane Main Business Overview

11.9.5 Oxyrane Latest Developments

11.10 NanoMedSyn

11.10.1 NanoMedSyn Company Information

11.10.2 NanoMedSyn Metachromatic Leukodystrophy Treatment Product Offered

11.10.3 NanoMedSyn Metachromatic Leukodystrophy Treatment Revenue, Gross

Margin and Market Share (2018-2023)

11.10.4 NanoMedSyn Main Business Overview

11.10.5 NanoMedSyn Latest Developments

11.11 Juventas Therapeutics

11.11.1 Juventas Therapeutics Company Information

11.11.2 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Product Offered

11.11.3 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.11.4 Juventas Therapeutics Main Business Overview

11.11.5 Juventas Therapeutics Latest Developments

11.12 GenSight Biologics

11.12.1 GenSight Biologics Company Information

11.12.2 GenSight Biologics Metachromatic Leukodystrophy Treatment Product Offered

11.12.3 GenSight Biologics Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.12.4 GenSight Biologics Main Business Overview

11.12.5 GenSight Biologics Latest Developments

11.13 Inozyme Pharma

11.13.1 Inozyme Pharma Company Information

11.13.2 Inozyme Pharma Metachromatic Leukodystrophy Treatment Product Offered

11.13.3 Inozyme Pharma Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.13.4 Inozyme Pharma Main Business Overview

11.13.5 Inozyme Pharma Latest Developments

11.14 ONL Therapeutics

11.14.1 ONL Therapeutics Company Information

11.14.2 ONL Therapeutics Metachromatic Leukodystrophy Treatment Product Offered

11.14.3 ONL Therapeutics Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.14.4 ONL Therapeutics Main Business Overview

11.14.5 ONL Therapeutics Latest Developments

11.15 AngioChem

11.15.1 AngioChem Company Information

11.15.2 AngioChem Metachromatic Leukodystrophy Treatment Product Offered

11.15.3 AngioChem Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.15.4 AngioChem Main Business Overview

11.15.5 AngioChem Latest Developments

11.16 Cabaletta Bio

11.16.1 Cabaletta Bio Company Information

11.16.2 Cabaletta Bio Metachromatic Leukodystrophy Treatment Product Offered

11.16.3 Cabaletta Bio Metachromatic Leukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.16.4 Cabaletta Bio Main Business Overview

11.16.5 Cabaletta Bio Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Metachromatic Leukodystrophy Treatment Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of Tablet

Table 3. Major Players of Capsule

Table 4. Major Players of Others

Table 5. Metachromatic Leukodystrophy Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 6. Global Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 7. Global Metachromatic Leukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 8. Metachromatic Leukodystrophy Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 9. Global Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 10. Global Metachromatic Leukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 11. Global Metachromatic Leukodystrophy Treatment Revenue by Players (2018-2023) & (\$ Millions)

Table 12. Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Player (2018-2023)

Table 13. Metachromatic Leukodystrophy Treatment Key Players Head office and Products Offered

Table 14. Metachromatic Leukodystrophy Treatment Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Metachromatic Leukodystrophy Treatment Market Size by Regions 2018-2023 & (\$ Millions)

Table 18. Global Metachromatic Leukodystrophy Treatment Market Size Market Share by Regions (2018-2023)

Table 19. Global Metachromatic Leukodystrophy Treatment Revenue by Country/Region (2018-2023) & (\$ millions)

Table 20. Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Country/Region (2018-2023)

Table 21. Americas Metachromatic Leukodystrophy Treatment Market Size by Country (2018-2023) & (\$ Millions)

Table 22. Americas Metachromatic Leukodystrophy Treatment Market Size Market Share by Country (2018-2023)

Table 23. Americas Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 24. Americas Metachromatic Leukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 25. Americas Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 26. Americas Metachromatic Leukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 27. APAC Metachromatic Leukodystrophy Treatment Market Size by Region (2018-2023) & (\$ Millions)

Table 28. APAC Metachromatic Leukodystrophy Treatment Market Size Market Share by Region (2018-2023)

Table 29. APAC Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 30. APAC Metachromatic Leukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 31. APAC Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 32. APAC Metachromatic Leukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 33. Europe Metachromatic Leukodystrophy Treatment Market Size by Country (2018-2023) & (\$ Millions)

Table 34. Europe Metachromatic Leukodystrophy Treatment Market Size Market Share by Country (2018-2023)

Table 35. Europe Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 36. Europe Metachromatic Leukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 37. Europe Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 38. Europe Metachromatic Leukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 39. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size by Region (2018-2023) & (\$ Millions)

Table 40. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size

Market Share by Region (2018-2023)

Table 41. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 42. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Table 43. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 44. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Table 45. Key Market Drivers & Growth Opportunities of Metachromatic Leukodystrophy Treatment

Table 46. Key Market Challenges & Risks of Metachromatic Leukodystrophy Treatment

Table 47. Key Industry Trends of Metachromatic Leukodystrophy Treatment

Table 48. Global Metachromatic Leukodystrophy Treatment Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 49. Global Metachromatic Leukodystrophy Treatment Market Size Market Share Forecast by Regions (2024-2029)

Table 50. Global Metachromatic Leukodystrophy Treatment Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 51. Global Metachromatic Leukodystrophy Treatment Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 52. ArmaGen, Inc. Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 53. ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Product Offered

Table 54. ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 55. ArmaGen, Inc. Main Business

Table 56. ArmaGen, Inc. Latest Developments

Table 57. GlaxoSmithKline Plc Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 58. GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Product Offered

Table 59. GlaxoSmithKline Plc Main Business

Table 60. GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 61. GlaxoSmithKline Plc Latest Developments

Table 62. Recursion Pharmaceuticals, Inc. Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 63. Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment

Product Offered

Table 64. Recursion Pharmaceuticals, Inc. Main Business

Table 65. Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 66. Recursion Pharmaceuticals, Inc. Latest Developments

Table 67. RegenxBio, Inc. Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 68. RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Product Offered

Table 69. RegenxBio, Inc. Main Business

Table 70. RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 71. RegenxBio, Inc. Latest Developments

Table 72. Takeda Pharmaceutical Company Limited Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 73. Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Product Offered

Table 74. Takeda Pharmaceutical Company Limited Main Business

Table 75. Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 76. Takeda Pharmaceutical Company Limited Latest Developments

Table 77. Orchard Therapeutics Plc Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 78. Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Product Offered

Table 79. Orchard Therapeutics Plc Main Business

Table 80. Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 81. Orchard Therapeutics Plc Latest Developments

Table 82. Magenta Therapeutics Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 83. Magenta Therapeutics Metachromatic Leukodystrophy Treatment Product Offered

Table 84. Magenta Therapeutics Main Business

Table 85. Magenta Therapeutics Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 86. Magenta Therapeutics Latest Developments

Table 87. Shire Plc Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 88. Shire Plc Metachromatic Leukodystrophy Treatment Product Offered

Table 89. Shire Plc Main Business

Table 90. Shire Plc Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 91. Shire Plc Latest Developments

Table 92. Oxyrane Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 93. Oxyrane Metachromatic Leukodystrophy Treatment Product Offered

Table 94. Oxyrane Main Business

Table 95. Oxyrane Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 96. Oxyrane Latest Developments

Table 97. NanoMedSyn Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 98. NanoMedSyn Metachromatic Leukodystrophy Treatment Product Offered

Table 99. NanoMedSyn Main Business

Table 100. NanoMedSyn Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 101. NanoMedSyn Latest Developments

Table 102. Juventas Therapeutics Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 103. Juventas Therapeutics Metachromatic Leukodystrophy Treatment Product Offered

Table 104. Juventas Therapeutics Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 105. Juventas Therapeutics Main Business

Table 106. Juventas Therapeutics Latest Developments

Table 107. GenSight Biologics Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 108. GenSight Biologics Metachromatic Leukodystrophy Treatment Product Offered

Table 109. GenSight Biologics Main Business

Table 110. GenSight Biologics Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 111. GenSight Biologics Latest Developments

Table 112. Inozyme Pharma Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 113. Inozyme Pharma Metachromatic Leukodystrophy Treatment Product Offered

Table 114. Inozyme Pharma Main Business

Table 115. Inozyme Pharma Metachromatic Leukodystrophy Treatment Revenue (\$

million), Gross Margin and Market Share (2018-2023)

Table 116. Inozyme Pharma Latest Developments

Table 117. ONL Therapeutics Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 118. ONL Therapeutics Metachromatic Leukodystrophy Treatment Product Offered

Table 119. ONL Therapeutics Main Business

Table 120. ONL Therapeutics Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 121. ONL Therapeutics Latest Developments

Table 122. AngioChem Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 123. AngioChem Metachromatic Leukodystrophy Treatment Product Offered

Table 124. AngioChem Main Business

Table 125. AngioChem Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 126. AngioChem Latest Developments

Table 127. Cabaletta Bio Details, Company Type, Metachromatic Leukodystrophy Treatment Area Served and Its Competitors

Table 128. Cabaletta Bio Metachromatic Leukodystrophy Treatment Product Offered

Table 129. Cabaletta Bio Main Business

Table 130. Cabaletta Bio Metachromatic Leukodystrophy Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 131. Cabaletta Bio Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Metachromatic Leukodystrophy Treatment Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate 2018-2029 (\$ Millions)
- Figure 6. Metachromatic Leukodystrophy Treatment Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Figure 7. Metachromatic Leukodystrophy Treatment Sales Market Share by Country/Region (2022)
- Figure 8. Metachromatic Leukodystrophy Treatment Sales Market Share by Country/Region (2018, 2022 & 2029)
- Figure 9. Global Metachromatic Leukodystrophy Treatment Market Size Market Share by Type in 2022
- Figure 10. Metachromatic Leukodystrophy Treatment in Hospital
- Figure 11. Global Metachromatic Leukodystrophy Treatment Market: Hospital (2018-2023) & (\$ Millions)
- Figure 12. Metachromatic Leukodystrophy Treatment in Clinic
- Figure 13. Global Metachromatic Leukodystrophy Treatment Market: Clinic (2018-2023) & (\$ Millions)
- Figure 14. Metachromatic Leukodystrophy Treatment in Laboratory
- Figure 15. Global Metachromatic Leukodystrophy Treatment Market: Laboratory (2018-2023) & (\$ Millions)
- Figure 16. Metachromatic Leukodystrophy Treatment in Others
- Figure 17. Global Metachromatic Leukodystrophy Treatment Market: Others (2018-2023) & (\$ Millions)
- Figure 18. Global Metachromatic Leukodystrophy Treatment Market Size Market Share by Application in 2022
- Figure 19. Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Player in 2022
- Figure 20. Global Metachromatic Leukodystrophy Treatment Market Size Market Share by Regions (2018-2023)
- Figure 21. Americas Metachromatic Leukodystrophy Treatment Market Size 2018-2023 (\$ Millions)
- Figure 22. APAC Metachromatic Leukodystrophy Treatment Market Size 2018-2023 (\$

Millions)

Figure 23. Europe Metachromatic Leukodystrophy Treatment Market Size 2018-2023 (\$ Millions)

Figure 24. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size 2018-2023 (\$ Millions)

Figure 25. Americas Metachromatic Leukodystrophy Treatment Value Market Share by Country in 2022

Figure 26. United States Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Canada Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 28. Mexico Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 29. Brazil Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 30. APAC Metachromatic Leukodystrophy Treatment Market Size Market Share by Region in 2022

Figure 31. APAC Metachromatic Leukodystrophy Treatment Market Size Market Share by Type in 2022

Figure 32. APAC Metachromatic Leukodystrophy Treatment Market Size Market Share by Application in 2022

Figure 33. China Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Japan Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 35. Korea Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Southeast Asia Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 37. India Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 38. Australia Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 39. Europe Metachromatic Leukodystrophy Treatment Market Size Market Share by Country in 2022

Figure 40. Europe Metachromatic Leukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Figure 41. Europe Metachromatic Leukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Figure 42. Germany Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 43. France Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 44. UK Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 45. Italy Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 46. Russia Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 47. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size Market Share by Region (2018-2023)

Figure 48. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size Market Share by Type (2018-2023)

Figure 49. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size Market Share by Application (2018-2023)

Figure 50. Egypt Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 51. South Africa Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 52. Israel Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Turkey Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 54. GCC Country Metachromatic Leukodystrophy Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 55. Americas Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 56. APAC Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 57. Europe Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 58. Middle East & Africa Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 59. United States Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 60. Canada Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 61. Mexico Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$

Millions)

Figure 62. Brazil Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 63. China Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 64. Japan Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 65. Korea Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 66. Southeast Asia Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 67. India Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 68. Australia Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 69. Germany Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 70. France Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 71. UK Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 72. Italy Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 73. Russia Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 74. Spain Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 75. Egypt Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 76. South Africa Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 77. Israel Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 78. Turkey Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 79. GCC Countries Metachromatic Leukodystrophy Treatment Market Size 2024-2029 (\$ Millions)

Figure 80. Global Metachromatic Leukodystrophy Treatment Market Size Market Share Forecast by Type (2024-2029)

Figure 81. Global Metachromatic Leukodystrophy Treatment Market Size Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Metachromatic Leukodystrophy Treatment Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/G3C2AB3E4B9FEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3C2AB3E4B9FEN.html>